Anavex Life Sciences Investor Relations Material
Latest events
Q1 2025
Anavex Life Sciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Anavex Life Sciences Corp
Access all reports
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. The company's lead drug candidate is 2-73 that has completed phase II clinical trial for the treatment of Alzheimer's disease. Its programs also includes ANAVEX 3-71, which is in pre-clinical testing for the treatment of amyotrophic lateral sclerosis disease; and ANAVEX 1-41, a pre-clinical stage small molecule compound for the treatment of epilepsy.
Key slides for Anavex Life Sciences Corp
Investor Presentation
Anavex Life Sciences Corp
H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Anavex Life Sciences Corp
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
AVXL
Country
🇺🇸 United States